Deep brain stimulation based on the wireless magnetically localised and ultrasonically actuated micro-robot

Informations projet

DBSBOT

N° de convention de subvention: 101109050

DOI

10.3030/101109050

Projet clôturé le 30 Janvier 2025

Date de signature de la CE 20 Mars 2023

Date de début 1 Avril 2023

Date de fin 31 Mars 2025

Financé au titre de

• Marie Skłodowska-Curie Actions (MSCA)

Coût total

Aucune donnée

Contribution de l’UE

€ 173 847,36

Coordonné par

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany

Periodic Reporting for period 1 - DBSBOT (Deep brain stimulation based on the wireless magnetically localised and ultrasonically actuated micro-robot)

Période du rapport: 2023-04-01 au 2025-03-31

Résumé du contexte et des objectifs généraux du projet

Neurological disorders, such as Alzheimer's and Parkinson's diseases, have become one of the most pressing health problems in the world. Traditional therapies like Deep Brain Stimulation (DBS) rely on invasive, wired systems that pose risks of infection and tissue damage. To address these limitations, this project aims to develop a pioneering solution: wireless, biocompatible microrobots for minimally invasive DBS. These microrobots use magnetic fields for precise navigation within the brain’s cerebrospinal fluid and ultrasound - powered piezoelectric materials to deliver electrical stimulation, bypassing the need for implanted electrodes.

The project aligns with the EU’s Brain Research Strategy, which utilizes innovative technologies to advance understanding and treatment of neurological diseases. By integrating robotics, material science, and biomedical engineering, the microrobots aim to reduce surgical risks, improve patient quality of life, and lower healthcare costs.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The project successfully developed and validated novel ultrasound-powered piezoelectric microrobots for deep brain stimulation (DBS) with precise positioning, achieving the following key milestones:

1. Device Development
(1)Designed and fabricated micro-scale piezoelectric robots using two-photon lithography, which are capable of converting ultrasonic energy into electrical stimulation pulses.
(2)Integrated magnetic nanoparticles to enable precise spatial control under the guidance of an external magnetic field.

2. In Vitro Validation

(1)Demonstrated effective responses in human SH-SY5Y neural cells under ultrasound stimulations.
(2)Maintained stable performance for more than 30 days without material degradation.

These technical achievements represent a significant advance over conventional DBS systems, eliminating the risks of invasive operations. The project has generated two drafted journal article manuscripts and paved the road for future development of in vivo investigations and foundation for clinical translation.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

1. Technical Achievements:
(1)Successfully developed ultrasound-powered piezoelectric microrobots (50-80μm scale) using two-photon lithography, demonstrating precise energy conversion from ultrasonic waves to electrical stimulation pulses.
(2)Achieved sub-millimeter positioning accuracy (≤10 μm) through integrated magnetic nanoparticle guidance.
(3)Validated neural stimulation capability in human SH-SY5Y cell models, showing biocompatibility after 3-day cell viability tests.

2. Potential Impacts:
(1)Clinical Transformation: Could improve DBS therapy by eliminating risks associated with implanted needles to reduce infection rates.
(2)Research Advancement: Enables new neuromodulation studies through minimally invasive and precise positioning.

3. Key Research Needs for Further Development:
(1)In vivo validation in Parkinson's disease animal models.
(2)Long-term biocompatibility studies (6-12 months).
(3)Optimization for different brain regions/targets.
(4)Preclinical safety/efficacy data package for regulatory submission.

4. Commercialization Support Requirements:
(1)Partnership development with neurotech manufacturers.
(2)Regulatory affairs expertise for medical device approval.

These results demonstrate progress toward showing the possibility of replacing current DBS systems. Successful translation could benefit an estimated 3-5 million potential patients worldwide.

The diagram of microrobots for deep brain stimulation